ABCA1 | ATP-binding cassette, sub-family A (ABC1), member 1 | Disease related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Transporters
| | | | | Expressed in all |
ABCC1 | ATP-binding cassette, sub-family C (CFTR/MRP), member 1 | Cancer-related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters
| | | | | Expressed in all |
ABCC2 | ATP-binding cassette, sub-family C (CFTR/MRP), member 2 | Cancer-related genes Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters
| | | | | Group enriched |
ABCC8 | ATP-binding cassette, sub-family C (CFTR/MRP), member 8 | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
ACE | Angiotensin I converting enzyme | Candidate cardiovascular disease genes CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Group enriched |
ACE2 | Angiotensin I converting enzyme 2 | Enzymes FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enhanced |
ACHE | Acetylcholinesterase (Yt blood group) | Blood group antigen proteins Enzymes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enriched |
ADORA1 | Adenosine A1 receptor | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
ADORA2A | Adenosine A2a receptor | Cancer-related genes FDA approved drug targets G-protein coupled receptors Predicted intracellular proteins Predicted membrane proteins
| | | | | Mixed |
ADORA2B | Adenosine A2b receptor | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
ADORA3 | Adenosine A3 receptor | FDA approved drug targets G-protein coupled receptors Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
ADRA1A | Adrenoceptor alpha 1A | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
ADRA1B | Adrenoceptor alpha 1B | Cancer-related genes FDA approved drug targets G-protein coupled receptors Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
ADRA1D | Adrenoceptor alpha 1D | FDA approved drug targets G-protein coupled receptors Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
ADRA2A | Adrenoceptor alpha 2A | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Mixed |
ADRA2B | Adrenoceptor alpha 2B | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Mixed |
ADRA2C | Adrenoceptor alpha 2C | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
ADRB1 | Adrenoceptor beta 1 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
ADRB2 | Adrenoceptor beta 2, surface | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Transporters
| | | | | Mixed |
ADRB3 | Adrenoceptor beta 3 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
AGTR1 | Angiotensin II receptor, type 1 | Disease related genes FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Transporters
| | | | | Group enriched |
ALK | Anaplastic lymphoma receptor tyrosine kinase | Cancer-related genes CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
ANO1 | Anoctamin 1, calcium activated chloride channel | FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Transporters
| | | | | Mixed |
ASIC1 | Acid-sensing (proton-gated) ion channel 1 | FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enriched |
ATP1A1 | ATPase, Na+/K+ transporting, alpha 1 polypeptide | Cancer-related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters
| | | | | Expressed in all |
ATP2C1 | ATPase, Ca++ transporting, type 2C, member 1 | Disease related genes Enzymes FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Expressed in all |
ATP4A | ATPase, H+/K+ exchanging, alpha polypeptide | Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters
| | | | | Tissue enriched |
AVPR1A | Arginine vasopressin receptor 1A | FDA approved drug targets G-protein coupled receptors Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
AVPR1B | Arginine vasopressin receptor 1B | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Transporters
| | | | | Not detected |
AVPR2 | Arginine vasopressin receptor 2 | Disease related genes FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Transporters
| | | | | Mixed |
BCL2 | B-cell CLL/lymphoma 2 | Cancer-related genes Disease related genes FDA approved drug targets Mitochondrial proteins Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
BDKRB2 | Bradykinin receptor B2 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Mixed |
CA14 | Carbonic anhydrase XIV | Enzymes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
CA4 | Carbonic anhydrase IV | Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
CACNA1A | Calcium channel, voltage-dependent, P/Q type, alpha 1A subunit | Disease related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
CACNA1B | Calcium channel, voltage-dependent, N type, alpha 1B subunit | FDA approved drug targets Plasma proteins Predicted membrane proteins Voltage-gated ion channels
| | | | | Group enriched |
CACNA1C | Calcium channel, voltage-dependent, L type, alpha 1C subunit | Disease related genes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
CACNA1D | Calcium channel, voltage-dependent, L type, alpha 1D subunit | Cancer-related genes Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enhanced |
CACNA1F | Calcium channel, voltage-dependent, L type, alpha 1F subunit | Disease related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Mixed |
CACNA1G | Calcium channel, voltage-dependent, T type, alpha 1G subunit | FDA approved drug targets Plasma proteins Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enhanced |
CACNA1H | Calcium channel, voltage-dependent, T type, alpha 1H subunit | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
CACNA1I | Calcium channel, voltage-dependent, T type, alpha 1I subunit | FDA approved drug targets Plasma proteins Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enhanced |
CACNA1S | Calcium channel, voltage-dependent, L type, alpha 1S subunit | Disease related genes FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
CACNA2D1 | Calcium channel, voltage-dependent, alpha 2/delta subunit 1 | FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins Transporters
| | | | | Mixed |
CACNG1 | Calcium channel, voltage-dependent, gamma subunit 1 | FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Tissue enriched |
CALY | Calcyon neuron-specific vesicular protein | FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Group enriched |
CAMLG | Calcium modulating ligand | FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Transporters
| | | | | Expressed in all |
CASR | Calcium-sensing receptor | Disease related genes FDA approved drug targets G-protein coupled receptors Plasma proteins Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
CCKAR | Cholecystokinin A receptor | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Group enriched |
CCKBR | Cholecystokinin B receptor | Cancer-related genes FDA approved drug targets G-protein coupled receptors Predicted intracellular proteins Predicted membrane proteins
| | | | | Group enriched |